Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vytorin, Zetia Labeling Adds Precaution On Cyclosporine Coadministration

This article was originally published in The Pink Sheet Daily

Executive Summary

Revised labeling for the Merck/Schering-Plough products recommends caution when coadministering ezetimibe and cyclosporine. In healthy patients, coadministration of cyclosporine and ezetimibe was associated with a 15% increase in cyclosporine AUC, labeling states.

You may also be interested in...



Zetia Labeling Adds Myopathy/Rhabdomyolysis Precaution

Revised labeling for Merck's lipid-lowering therapy notes most cases of rhabdomyolysis occurred in patients who had been taking statins. The skeletal muscle precaution follows the recent addition of a precaution against use with cyclosporine.

Zetia Labeling Adds Myopathy/Rhabdomyolysis Precaution

Revised labeling for Merck's lipid-lowering therapy notes most cases of rhabdomyolysis occurred in patients who had been taking statins. The skeletal muscle precaution follows the recent addition of a precaution against use with cyclosporine.

Schering/Merck Zetia 6% Market Share Is 1% Ahead Of Goal

Prescription growth for the cholesterol drug Zetia has not come at the expense of the Zetia/Zocor fixed-dose combination Vytorin, Schering says. The penetration rate for Vytorin on managed care formularies is over 75%, the company says.

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel